Latest Breaking News On - Molecular targets - Page 7 : comparemela.com

KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/Refractory Solid Tumors

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).

United statesMiguel villalona caleroTherapeutics researchDepartment of medical oncologyInternational conference on molecularEarly phase therapeutics programMolecular targetsMedical oncologyDevelopmental cancer therapeutics programThe selective cdk9 inhibitor kb 0742Heavily pretreated patients with relapsed refractoryRanscriptionally addicted solid tumorsPhase 1 trial nct047186752023 aacr nci eortc international conference on molecular targets and cancer therapeutics

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Provides fiscal year 2025 revenue guidance of $12 - $16 millionUS pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) u.

United statesIsrael generalSteve lisiKori ann taylorCorey davisEdward bargerVizient incExchange commissionInternational conference on molecularLifesci advisorsViral communityInnovative technologyDrug administrationSociety for immunotherapy conferenceCystic fibrosis foundationHebrew university of jerusalem

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesIsrael generalSteve lisiCorey davisKori ann taylorEdward bargerInnovative technologyCystic fibrosis foundationVizient incDrug administrationGlobenewswire incLifesci advisorsSolid tumor programViral communityInternational conference on molecularCancer ltd

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

United statesNew yorkJohns hopkinsIntrahepatic cholangiocarcinomaMarina barettiExelixis incyteSidney kimmel comprehensive cancer centerInternational conference on molecularJohns hopkins medicineLiaoc yMolecular targetsCancer therapeuticsBiliary tract cancer

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL)Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 studyPrioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2.

Adicet bioJanhavi mohiteChen schorAnne bowdidgeInternational conference on molecularSociety for immunotherapy of cancerDrug administrationDevelopment for solid tumorsAdicet bio incDevelopment rd expensesStern investor relations incNew drug applicationChief executive officerOperational highlightsInternational conferenceMolecular targets